Boston Scientific Corp
BSX103.640USD
-1.010-0.97%
Close 07/18, 16:00（ET）Quotes delayed by 15 min
153.30BMarket Cap
75.44P/E TTM
More Details of Boston Scientific Corp Company
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
Company Info
Ticker SymbolBSX
Company nameBoston Scientific Corp
IPO dateMay 19, 1992
Founded at1979
CEOMr. Michael F. (Mike) Mahoney
Number of employees53000
Security typeOrdinary Share
Fiscal year-endMay 19
Address300 Boston Scientific Way
CityMARLBOROUGH
Stock exchangeNYSE Consolidated
CountryUnited States of America
Postal code01752-1234
Phone15086834000
Websitehttps://www.bostonscientific.com/en-US/Home.html
Ticker SymbolBSX
IPO dateMay 19, 1992
Founded at1979
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Michael F. (Mike) Mahoney
Mr. Michael F. (Mike) Mahoney
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.75M
-3.25%
Mr. John E. Sununu
Mr. John E. Sununu
Independent Director
Independent Director
54.72K
+3.95%
Mr. Jonathan R. Monson
Mr. Jonathan R. Monson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
37.98K
+5.88%
Ms. Ellen M. Zane
Ms. Ellen M. Zane
Independent Director
Independent Director
37.02K
+5.96%
Mr. Vance R. Brown
Mr. Vance R. Brown
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
33.45K
+6.64%
Mr. David C. Habiger
Mr. David C. Habiger
Independent Director
Independent Director
5.63K
+58.67%
Mr. Yoshiaki Fujimori
Mr. Yoshiaki Fujimori
Independent Director
Independent Director
4.98K
+71.73%
Mr. Arthur Crosswell Butcher
Mr. Arthur Crosswell Butcher
Executive Vice President, Group President, MedSurg and Asia Pacific
Executive Vice President, Group President, MedSurg and Asia Pacific
--
--
Mr. Edward J. Ludwig
Mr. Edward J. Ludwig
Lead Independent Director
Lead Independent Director
--
--
Ms. Meghan Scanlon
Ms. Meghan Scanlon
Senior Vice President and President - Urology
Senior Vice President and President - Urology
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Michael F. (Mike) Mahoney
Mr. Michael F. (Mike) Mahoney
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.75M
-3.25%
Mr. John E. Sununu
Mr. John E. Sununu
Independent Director
Independent Director
54.72K
+3.95%
Mr. Jonathan R. Monson
Mr. Jonathan R. Monson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
37.98K
+5.88%
Ms. Ellen M. Zane
Ms. Ellen M. Zane
Independent Director
Independent Director
37.02K
+5.96%
Mr. Vance R. Brown
Mr. Vance R. Brown
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
33.45K
+6.64%
Mr. David C. Habiger
Mr. David C. Habiger
Independent Director
Independent Director
5.63K
+58.67%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Electrophysiology
730.00M
15.66%
Interventional Cardiology Therapies
697.00M
14.95%
Endoscopy
673.00M
14.43%
Peripheral Interventions
656.00M
14.07%
Urology
633.00M
13.57%
Other
1.27B
27.32%
By RegionUSD
Name
Revenue
Proportion
United States
2.96B
63.48%
EMEA (Europe, Middle East and Africa)
846.00M
18.14%
Asia Pacific
701.00M
15.03%
Latin America and Canada
155.00M
3.32%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Electrophysiology
730.00M
15.66%
Interventional Cardiology Therapies
697.00M
14.95%
Endoscopy
673.00M
14.43%
Peripheral Interventions
656.00M
14.07%
Urology
633.00M
13.57%
Other
1.27B
27.32%
Shareholding Stats
Updated: Wed, May 14
Updated: Wed, May 14
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.05%
Fidelity Management & Research Company LLC
7.94%
BlackRock Institutional Trust Company, N.A.
5.26%
State Street Global Advisors (US)
4.36%
PRIMECAP Management Company
2.47%
Other
70.92%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.05%
Fidelity Management & Research Company LLC
7.94%
BlackRock Institutional Trust Company, N.A.
5.26%
State Street Global Advisors (US)
4.36%
PRIMECAP Management Company
2.47%
Other
70.92%
Shareholder Types
Shareholders
Proportion
Investment Advisor
43.49%
Investment Advisor/Hedge Fund
37.01%
Hedge Fund
3.98%
Pension Fund
2.86%
Research Firm
2.45%
Bank and Trust
1.71%
Sovereign Wealth Fund
1.54%
Private Equity
0.20%
Insurance Company
0.19%
Other
6.56%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
2690
1.38B
93.52%
-4.76M
2025Q1
2744
1.39B
93.81%
-5.31M
2024Q4
2559
1.38B
93.61%
+1.09M
2024Q3
2417
1.37B
92.76%
-24.32M
2024Q2
2341
1.37B
93.29%
-18.17M
2024Q1
2227
1.37B
93.23%
-40.14M
2023Q4
2171
1.39B
94.95%
-25.34M
2023Q3
2110
1.39B
95.17%
-6.29M
2023Q2
2081
1.38B
95.67%
-15.63M
2023Q1
2012
1.36B
94.85%
-23.81M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
133.95M
9.05%
+1.70M
+1.28%
Mar 31, 2025
Fidelity Management & Research Company LLC
117.45M
7.94%
-3.75M
-3.09%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
77.81M
5.26%
+1.08M
+1.41%
Mar 31, 2025
State Street Global Advisors (US)
64.48M
4.36%
+514.79K
+0.80%
Mar 31, 2025
PRIMECAP Management Company
36.50M
2.47%
-432.72K
-1.17%
Mar 31, 2025
Wellington Management Company, LLP
33.20M
2.24%
-2.97M
-8.21%
Mar 31, 2025
Geode Capital Management, L.L.C.
31.80M
2.15%
+1.18M
+3.84%
Mar 31, 2025
Capital World Investors
28.56M
1.93%
+658.82K
+2.36%
Mar 31, 2025
Managed Account Advisors LLC
21.29M
1.44%
+3.60M
+20.36%
Mar 31, 2025
The Bollard Group, LLC
20.49M
1.39%
-242.40K
-1.17%
Mar 31, 2025
View more
Related ETFs
Updated: Sun, Jul 6
Updated: Sun, Jul 6
Name
Proportion
iShares U.S. Medical Devices ETF
11.13%
Goldman Sachs Future Health Care Equity ETF
8.57%
NYLI Healthy Hearts ETF
5.52%
iShares Health Innovation Active ETF
4.66%
Invesco Dorsey Wright Healthcare Momentum ETF
4.09%
JPMorgan Healthcare Leaders ETF
4.07%
Tema Heart & Health ETF
3.42%
Health Care Select Sector SPDR Fund
3.23%
Congress Large Cap Growth ETF
3.2%
Global X Aging Population ETF
3.18%
View more
iShares U.S. Medical Devices ETF
Proportion11.13%
Goldman Sachs Future Health Care Equity ETF
Proportion8.57%
NYLI Healthy Hearts ETF
Proportion5.52%
iShares Health Innovation Active ETF
Proportion4.66%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion4.09%
JPMorgan Healthcare Leaders ETF
Proportion4.07%
Tema Heart & Health ETF
Proportion3.42%
Health Care Select Sector SPDR Fund
Proportion3.23%
Congress Large Cap Growth ETF
Proportion3.2%
Global X Aging Population ETF
Proportion3.18%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
